Slide 1: Earnings Call - Q1 2021
www.viewray.com Earnings Call - Q1 2021 May 6, 2021 Exhibit 99.2
Slide 2: Forward-looking statements disclaimer
This presentation has been prepared solely for use at this meeting and is intended for investors and analysts only. The material is given in conjunction with an oral presentation and should not be taken out of context. Unless the context requires otherwise, references to “ViewRay,” “the company,” “w
Slide 3: Our mission: Treat and prove what others can't
Our mission: Treat and prove what others can’t. ©2021 ViewRay, Inc. All rights reserved.
Slide 4: MRIdian Benefits
MRIdian Benefits ©2021 ViewRay, Inc. All rights reserved. MRIdian
Slide 5: Patients Treated Annually
Patients Treated Annually ©2021 ViewRay, Inc. All rights reserved.
Slide 6: What We Achieved: Q1 2021 Financial Results
What We Achieved Q1 2021 Financial Results 1 Excluding net proceeds from the January 2021 equity offering. ©2021 ViewRay, Inc. All rights reserved. 1Q 2020 1Q 2021
Slide 7: Customers' Definition of Clinical Success
Customers’ Definition of Clinical Success MRIdian SMART: Stereotactic MR-guided Adaptive Radiotherapy Among alternatives in the clinical landscape, we have found only MRIdian’s evidence fits this criteria. Ablative Dose Tight Margins No Fiducials No or Low Grade 3 Toxicity The MRIdian 5 1 2 3 5 5 or
Slide 8: MRIdian Clinical Pipeline
MRIdian Clinical Pipeline Prospective studies. Larger ‘N’ Confirm signals in key tumor sites Safety and Efficacy endpoints Randomized controlled trials Comparative Safety and efficacy endpoints 60+ investigator-initiated trials Feasibility Explore new indications/expand SMART Reduce fx and improve w
Slide 9: Customers are purchasing multiple MRIdian systems
Customers are purchasing multiple MRIdian systems ©2021 ViewRay, Inc. All rights reserved. = Top and bottom line impact for customers + MRIdian 51 Clinical Strategic Economic MRIdian Value Chain MRIdian SMART
Slide 10: MRIdian Enables Progression of Therapy
MRIdian Enables Progression of Therapy Customers desire and patients demand shorter courses of effective treatment MRIdian SMART ONE1: Multicenter, single-arm phase 1, single-fraction therapy in both primary tumors and oligomets located in lung, pancreas, liver, kidney, adrenal, and lymph nodes MRId
Slide 11: Pipeline Update
Pipeline Update ©2021 ViewRay, Inc. All rights reserved. + This presentation is intended for investors and analysts only. Some features described herein are not and may never be cleared or approved for sale in all markets.
Slide 12: Financial Results Q1 2021
@ viewray FINANCIAL RESULTS Q1 2021
Slide 13: Financial Highlights
Backlog increased 15% YoY Strong customer engagement despite the challenges posed by the ongoing pandemic Revenue increased 9% U.S. revenue: $7.4 million Outside of U.S. revenue: $8.1 million Gross margin improved by 17% Product gross margin 7% Service gross margin -12% Net loss decreased 3% Operati
Slide 14: ViewRay: Visibly Better
@ VIEW RAY'|VISIBLY BETTER
Slide 15: Presentation Citations
Presentation Citations Slide 3 Internal and historical company data 04/15/2021 MRIdian log data Slide 4 12/31/2020 MRIdian log data, 78.1% SBRT treatment on MRIdian (~80%) Centers for Medicare & Medicaid Services, RO Episode File, 2017 data published in 2019 Caudell, J., et al. (2014). Altered Fract
Slide 16: Citations: Slide 1 references
Slide 9 1. - Henke, L., et al. (2018). Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiotherapy and Oncology, 126(3), 519-526; Henke LE, et al. Stereotactic mr-guided onlin
Slide 17: ViewRay
@ viewray